Lung Cancer

Tecemotide (INN; emepepimut-S (USAN); formerly known as BLP25 or EMD 531444) is a synthetic lipopeptide that is used as antigen in an investigational therapeutic cancer vaccine (formerly known as Stimuvax, L-BLP25, BLP25 liposomal vaccine, or BLP25 liposome vaccine).

Read more in the app

Diabetes drug reduces drug resistance in lung cancer, improving chemotherapy effectiveness

Study supports precision radiation therapy in lung cancer - EurekAlert

Honeybees can “smell” lung cancer

Artificial intelligence blood test provides a reliable way to identify lung cancer - EurekAlert

Artificial intelligence blood test provides a reliable way to identify lung cancer

Research spotlight: AI enabled body composition analysis predicts outcomes for patients with lung cancer treated with ... - EurekAlert

Ex-cigarette smokers who vape may be at higher risk for lung cancer - EurekAlert

Vaping After Quitting Smoking: A Potential Path to Lung Cancer

FDA Approves Amgen Drug for Persistently Deadly Form of Lung Cancer

Genetically engineered dendritic cells enhance the power of immunotherapy against lung cancer

AI may predict spread of lung cancer to brain

Unlocking Early Detection of Lung Cancer With MIT’s Inhalable Nanosensors

Cancer Caught in the Act: Scientists Reveal How One Type of Lung Cancer Can Transform Into Another

AstraZeneca unveils successes in treatment of lung cancer

Nanobubble Breakthrough: Unlocking the Power of Inhaled Therapy for Lung Cancer

How one type of lung cancer can transform into another

A type of allergy medicine might help treat lung cancer

Researchers Identify an Unexpected Predictor of Lung Cancer’s Return

Significant progress in small-cell lung cancer research

Lung cancer deaths cut in half with AstraZeneca pill